Company Analysis
Sign in

Silo Pharma, Inc. (SILO)

Nasdaq: SILO · Pharmaceutical Preparations · Sarasota, FL · filing with the SEC since 2011
Full chart Alerts Compare
Grade4.5
◀ Past 4.8● Present 4.3▶ Future 4.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Silo Pharma, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.5/10
◀ Past4.825% of the headline
● Present4.335% of the headline
▶ Future4.640% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.8/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
2.1/10

Has it survived what it has been through?

5 warning events since 2017; the latest 2025-12-29.

weight 22% of this tense · 21st percentile among 497 sector filers · read for itself

From the record

Silo Pharma, Inc.'s filings since 2017 show 5 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2025-12-29); an auditor change (8-K item 4.01, the latest 2019-01-22); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2019-04-01) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
7.3/10

What has it actually done, year after year?

+10.1% a year over 6 filed years; profitable in 1 of 7.

weight 45% of this tense · 73rd percentile among 323 sector filers · read for its customers

From the record

Silo Pharma, Inc.'s 6 filed years say what it did: revenue went from $41 thousand in fiscal 2019 to $72 thousand in fiscal 2025, up 10.1% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 1 of 7 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span10.1%bottom 44% of its family
  • the share of years revenue rosetop 8% of its family
  • the share of filed years with a profittop 33% of its family
  • the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
3.0/10

How has it treated the people who own it?

SI estimate 3.0/10, confidence 35 of 100 (one part).

weight 33% of this tense · 30th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 30% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Silo Pharma, Inc.'s shareholder treatment is put at 3.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 30% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.3/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
3.6/10

Is it financially healthy right now?

ROE -67%: lost 67¢ per shareholder dollar. Leverage 17%: owes 17¢ per asset dollar.

weight 45% of this tense · 36th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Silo Pharma, Inc. lost about 67 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 17 cents per dollar of assets, and net share issuance: its share count grew 127.8% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 27% of its family
  • return on equitybottom 42% of its family
  • gross profit against assetsbottom 9% of its family
  • the share count against the year beforebottom 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
1.9/10

How strong is its position in its industry?

bottom 19% of 315 in its family; net margin -5863.5%.

weight 22% of this tense · 19th percentile among 315 sector filers · read for its customers

From the record

Silo Pharma, Inc.'s standing among 315 graded names in its industry family: revenue of $72 thousand in fiscal 2025 ranks in the bottom 7% by size; a net margin of -5863.5% ranks in the bottom 14%; revenue growth of 0% a year over the last 3 filed years ranks in the bottom 38% (its annual reports).

What it rests on

  • revenue against the family$72,102bottom 7% of its family
  • net margin-5863.5%bottom 14% of its family
  • three-year revenue growth0.0%bottom 38% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
6.8/10

What are the people in charge doing?

SI estimate 6.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 68th percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the chief executive's years under the title, which ranks in the top 32% of 415 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
What the record cannot read
Fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title.
How it was reasoned
one part: the chief executive's years on the record, the one part on file, ranked among 415 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Silo Pharma, Inc.'s leadership is put at 6.8 of 10 with a confidence of 35 of 100, because read from one part only, the chief executive's years under the title, which ranks in the top 32% of 415 in its family; fewer than two of the three parts can be read: officer and director changes against the people in charge, the years the people in charge have been filing, the chief executive's years under the title. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.6/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
4.8/10

How much room does it have to grow?

bottom 48% of 273 in its family for room to expand.

weight 33% of this tense · 48th percentile among 273 sector filers · read for itself

From the record

Silo Pharma, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $5 million against no long-term debt tagged leaves 62.4% of its assets as net cash, top 26% of its family; cash from operations less capital spending is -6464.9% of revenue (bottom 10%); a gross margin of 38.6% (bottom 21%); research spending of 2996.9% of revenue (top 12%) (its annual report).

What it rests on

  • cash less debt against assets62.4%top 26% of its family
  • cash from operations less capital spending against revenue-6464.9%bottom 10% of its family
  • gross margin38.6%bottom 21% of its family
  • research spending against revenue2996.9%top 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
4.9/10

What could actually drive growth from here?

bottom 49% of 306 in its family for growth drivers.

weight 45% of this tense · 49th percentile among 306 sector filers · read for its customers

From the record

Silo Pharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 0% a year over the last three filed years against 10.1% over all 6, slowing (bottom 33% of its family); the newest year grew 0% (bottom 38%); research spending grew 18.9% a year (top 25%) (its annual reports). Silo Pharma, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-10.1 points a yearbottom 33% of its family
  • the newest year's revenue growth0.0%bottom 38% of its family
  • three-year growth of research spending18.9%top 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
3.7/10

Did its newest year beat what its own record pointed to?

bottom 37% of 233 in its family for expectations against reality.

weight 22% of this tense · 37th percentile among 233 sector filers · read for its shareholders

From the record

Silo Pharma, Inc.'s newest year against its own record: revenue of $72 thousand in fiscal 2025 came in 0% above the $72 thousand its prior three years' pace pointed to (top 46% of its family); net income of $4 million against a prior three-year average of $4 million (bottom 39%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 17%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace0.0%top 46% of its family
  • net income against the prior three years' average-6%bottom 39% of its family
  • net margin against its prior averagedown more than 100 pointsbottom 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SILO · research, not advice